DNA methylation signatures from tissue and cell-free DNA in alpha-1 antitrypsin deficiency mirror clinical pathologies providing a potential non-invasive tool to monitor liver disease progression
Alpha-1 antitrypsin deficiency (AATD) is a serpinopathy in which mutations in the SERPINA1 gene cause misfolding of alpha-1 antitrypsin (Z-AAT), leading to hepatic protein accumulation, proteotoxic stress, inflammation, fibrosis, and an increased risk of hepatocellular carcinoma. Despite a uniform genetic mutation in most affected individuals, liver disease severity varies, reflecting contributions from environmental exposures and epigenetic heterogeneity (e.g. DNA methylation). As RNA-interference therapy has emerged as a promising treatment, understanding how epigenetic variation relates to the clinical and histopathologic features of AATD may provide insight into disease heterogeneity, progression, and therapeutic response. We analyzed a longitudinal cohort of ZZ-genotype AATD patients with paired liver biopsies, plasma cell-free DNA (cfDNA), and clinical data collected at baseline and 3-y follow-up. Genome-wide DNA methylation profiling of liver tissue identified 15 CpG clusters associated with liver disease severity, immune pathways, and clinical measures including METAVIR fibrosis score and γ-glutamyltransferase. Parallel methylation profiling of matched plasma-derived cfDNA identified eight analogous CpG clusters enriched for similar biological pathways and associated with clinical parameters. Integration of tissue and cfDNA datasets revealed fifty-one shared CpGs representing disease-associated methylation signatures, including loci such as ZFP57 that tracks with portal inflammation. We also identified a DNA methylation signature associated with fibrosis progression based on changes in METAVIR score. These findings demonstrate that liver- and cfDNA-derived DNA methylation signatures robustly stratify AATD patients by relevant measures of liver injury and fibrosis, supporting their potential as non-invasive biomarkers for diagnosis, prognosis, and monitoring responses to emerging therapies.
Authors
- Ryan T. Wagner (ORCID: https://orcid.org/0000-0002-6725-2064)
- Virginia Clark (ORCID: https://orcid.org/0000-0001-6719-3634)
- George W. Marek (ORCID: https://orcid.org/0000-0002-2995-3660)
- Keith D. Robertson (ORCID: https://orcid.org/0000-0002-7508-3328)
- Ryan A. Hlady (ORCID: https://orcid.org/0000-0002-2829-4237)
- Mark Brantly
- Liguo Wang
- Chen Liu
- Xia Zhao
Institutions
- Mayo Clinic (US)
- University of Florida Health (US)
- Yale University (US)
- University of Florida (US)
Publication Details
- Journal
- Epigenetics
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1080/15592294.2026.2760044
- Primary Topic
- Epigenetics and DNA Methylation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- American Liver Foundation